Friday, July 1, 2016

Juniper Pharma’s lidocaine vaginal gel data due in Q3

Juniper Pharma’s lidocaine vaginal gel data due in Q3

June 28, 2016 by · Leave a Comment 

Tweet Juniper Pharmaceuticals (NASDAQ:JNP) expects to report results in the third quarter from a Phase 2b clinical trial of its 10% lidocaine bioadhesive vaginal gel, COL-1077, a local anesthetic for pain from minimally invasive outpatient gynecological procedures. “There is no product like it on the market,” Frank Condella, president and CEO, says in an interview […]

Antibe to have Phase 2 pain data by third quarter

Antibe to have Phase 2 pain data by third quarter

June 21, 2016 by · Leave a Comment 

Tweet Antibe Therapeutics (OTCQB:ATBPF; TSX-V:ATE) expects to have data by the third quarter this year from a small Phase 2 study of its naproxen derivative, ATB-346, in patients with osteoarthritis in the knee. “ATB-346 was designed to deliver non-addictive pain relief with significantly less gastrointestinal and cardiovascular damage than is typically associated with the use […]

S1 Biopharma to start Phase 2b study in female HSDD by yearend

S1 Biopharma to start Phase 2b study in female HSDD by yearend

June 14, 2016 by · Leave a Comment 

Tweet Closely-held S1 Biopharma expects to initiate a Phase 2b study at the end of the year with its lead product candidate for female hypoactive sexual desire disorder (HSDD), Lorexys, and a Phase 2a program with a second therapy, Orexa, for male HSDD. “HSDD is characterized by a lack or absence of sexual fantasies and […]

ESSA Pharma takes unique approach to prostate cancer

ESSA Pharma takes unique approach to prostate cancer

June 7, 2016 by · Leave a Comment 

Tweet A marine sponge, Geodia lindgreni, native to Papua New Guinea may hold the key to a new approach in the treatment of prostrate cancer by ESSA Pharma (NASDAQ:EPIX; TSX:EPI). “Our scientific founders from the BC Cancer Agency and the University of British Columbia spent more than a decade conducting the basic biology research, identifying […]

Lipocine advancing pipeline, PDUFA for oral TRT

Lipocine advancing pipeline, PDUFA for oral TRT

May 31, 2016 by · Leave a Comment 

Tweet With a PDUFA date of June 28 for an FDA decision on its oral testosterone replacement therapy (TRT) product candidate, TLANDO, Lipocine’s (NASDAQ:LPCN) next two pipeline product candidates are advancing towards Phase 3 ready status this year. “We have a robust pipeline with a number of key milestones in 2016 besides the decision on […]

Delivra implementing U.S. expansion strategy for topical creams

Delivra implementing U.S. expansion strategy for topical creams

May 24, 2016 by · Leave a Comment 

Tweet The major initiative for Delivra (TSX-V:DVA) in 2016 is to introduce its flagship LivRelief topical pain and nerve creams to the U.S. market, initially through a U.S. web store and Amazon, and then through regional and national retailers, such as Walmart, Walgreens and CVS. “We are launching an aggressive digital campaign shortly, and later […]

ARIAD hopes to launch second oncology drug in early 2017

ARIAD hopes to launch second oncology drug in early 2017

May 17, 2016 by · Leave a Comment 

Tweet ARIAD Pharmaceuticals (NASDAQ:ARIA) is hoping to receive FDA approval to commercialize in early 2017 its second orphan oncology product, brigatinib, for the treatment of certain genetic forms of non-small cell lung cancer. At the end of 2012, the company launched Iclusig (ponatinib) to treat patients with several genetic types of chronic myeloid leukemia. “As […]

In conversation with Rosario G. Cartagena

In conversation with Rosario G. Cartagena

May 10, 2016 by · Leave a Comment 

Tweet As a member of the Health Law Group at Fasken Martineau in Toronto, Rosario Cartagena provides advice on a variety of health law matters, including corporate governance, public policy, government relations, risk management, privacy, health regulatory compliance, and health research. She also regularly assists in drafting agreements, related to corporate governance and regulatory compliance across […]

Profound Medical readies pivotal clinical trial of TULSA-PRO

Profound Medical readies pivotal clinical trial of TULSA-PRO

May 3, 2016 by · Leave a Comment 

http://www.youtube.com/watch?v=Wyy5jLOi8ac’]

Tweet After receiving CE Mark approval last month of its minimally invasive transurethral ultrasound technology for the ablation of benign and malignant prostate tissue, known as TULSA-PRO, Profound Medical (TSX-V:PRN) plans to enroll 14 sites in the U.S., Canada and Europe in a pivotal trial for U.S. regulatory approval. “We have discussions ongoing with the […]

In conversation with Paul Gunn

In conversation with Paul Gunn

April 26, 2016 by · Leave a Comment 

http://www.youtube.com/watch?v=Acau04X2Utk’]

Tweet As president and CEO of closely-held Soricimed Biopharma, Paul Gunn parlayed a 20-year career as a financial executive into funding the startup of Soricimed along with a tech transfer in 2005 facilitated by Mount Allison University in Sackville, New Brunswick, Canada. Admittedly, he was new to biotech and drug development in those days, but […]

Next Page »

Email Newsletters with Constant Contact
Google+